The short answer: which should you consider first?
If your prostate cancer has stopped responding to hormone therapy, your doctor is likely discussing next steps. You may choose between Lu-177 PSMA therapy (sold as Pluvicto) and taxane chemotherapy (docetaxel or cabazitaxel). One factor matters most: whether your tumors show the PSMA protein, which a PSMA-PET scan can detect. If the scan is positive, Lu-177 PSMA therapy may work before or after chemotherapy. If the scan is negative or shows low levels, taxane chemotherapy is usually the next step.
This article is for patients with metastatic castration-resistant prostate cancer (mCRPC) - prostate cancer that has spread and no longer responds to hormone therapy.
What does hormone therapy failure mean in prostate cancer?
Most prostate cancers depend on testosterone to grow. Hormone therapies called androgen deprivation therapy (ADT) and newer androgen receptor pathway inhibitors (ARPIs) such as enzalutamide, abiraterone, and darolutamide cut off that fuel supply. For a time, these treatments work well.
But cancer cells adapt. When PSA rises despite hormone therapy, or when scans show new or growing tumors, doctors call this castration-resistant disease. At this point, hormone therapy no longer works. You need a treatment that works differently. Two main options are Lu-177 PSMA therapy and taxane-based chemotherapy.
How do Lu-177 PSMA therapy and taxane chemotherapy work?
Lu-177 PSMA therapy (brand name Pluvicto) is a targeted treatment. Its full generic name is lutetium Lu-177 vipivotide tetraxetan. It's called a radioligand because it combines a targeting molecule with a radioactive payload. The targeting molecule finds a protein called PSMA (prostate-specific membrane antigen) on prostate cancer cells. Once it finds these cells, it delivers radiation directly to them. Nearby healthy tissue gets much less radiation than with whole-body chemotherapy. You can read more about this targeting process in the article How Lu-177 PSMA Works: Understanding PSMA Targeting and Theranostics.
Taxane chemotherapy works differently. Docetaxel and cabazitaxel are taxanes. They circulate in the bloodstream and disrupt how cells divide. Cancer cells divide faster, so the drugs hit them harder than most normal cells. But taxanes are not targeted. Healthy fast-dividing cells in bone marrow, hair follicles, and the gut lining are also affected. That's why the side effects look different from radioligand therapy.
How does Lu-177 PSMA compare with taxane chemotherapy?
| Factor | Lu-177 PSMA (Pluvicto) | Taxane Chemotherapy |
|---|---|---|
| How it works | Targeted radiation delivered to PSMA-expressing cancer cells | Disrupts cancer cell division systemically throughout the body |
| Key test required | PSMA-PET scan - positive result required before treatment | No PET scan required |
| Common side effects | Fatigue, dry mouth, nausea, low blood counts | Neutropenia, hair loss, peripheral neuropathy, fatigue |
| Hair loss | Not typical | Common with docetaxel |
| Main evidence base | VISION trial (post-taxane); PSMAfore trial (pre-taxane) | TAX 327 trial (docetaxel); TROPIC trial (cabazitaxel) |
| FDA approval status (2025) | Approved post-ARPI, pre- or post-taxane, requires PSMA-PET positive | Approved for mCRPC; docetaxel is standard first-line chemotherapy |
Trial references: VISION trial (PMC8555571); PSMAfore-based FDA 2025 expansion; TAX 327 and TROPIC trial data via NIH PMC review of chemotherapy in prostate cancer.
The key difference is that Lu-177 PSMA requires your tumors to show PSMA at a detectable level on a PET scan. If confirmed, Lu-177 PSMA may offer similar or better disease control with different, and often easier-to-manage, side effects than taxane chemotherapy. If PSMA expression is low or absent, taxane chemotherapy is the main systemic option.
Who is eligible for Lu-177 PSMA therapy?
The FDA expanded its approval of Pluvicto in March 2025 to cover two groups of mCRPC patients:
- Patients who have already received an ARPI and one or two taxane regimens - the original VISION trial indication.
- Patients who have received an ARPI and whose doctors consider it appropriate to delay taxane chemotherapy - based on the PSMAfore trial, added in the 2025 expansion.
In both cases, a positive PSMA-PET scan is required. In the VISION trial, positive meant tumor uptake visually greater than the liver on imaging. Not every mCRPC patient meets this standard. About 10 to 20 percent may have low or absent PSMA expression. If you have not yet had a PSMA-PET scan, the steps involved are explained in Preparing for Your PSMA PET Scan for Lu-177 Eligibility.
Your doctor will also check kidney function, bone marrow health, and overall fitness. Patients with fast-growing cancer in the liver or lungs may need urgent treatment, and your oncologist will discuss this carefully.
Before deciding, confirm your eligibility with a nuclear medicine team trained in radioligand therapy. Art of Healing Cancer can provide a Lu-177 eligibility review using your PSMA-PET results.
What the evidence shows
The VISION trial is the strongest evidence for Lu-177 PSMA therapy in mCRPC. It included 831 patients who had received an ARPI and one or two taxane regimens. Some received Lu-177 PSMA plus standard care, others received standard care alone. Those with Lu-177 PSMA had median overall survival of 15.3 months compared with 11.3 months.
But this comparison needs context. The VISION trial didn't compare Lu-177 directly against chemotherapy. It tested Lu-177 added to standard care versus standard care alone in patients who had finished taxane therapy. So the survival gain reflects what Lu-177 added in this heavily treated group, not whether Lu-177 beats chemotherapy at the same treatment stage.
The PSMAfore trial asked a different question: can Lu-177 PSMA work earlier, before chemotherapy? It included patients who had received one ARPI and whose doctors thought delaying taxane chemotherapy was appropriate. These patients got either Lu-177 PSMA or switched to a different ARPI. Lu-177 PSMA cut disease progression more, supporting earlier use in mCRPC for PSMA-positive patients.
The TAX 327 trial showed docetaxel improves survival compared with older chemotherapy for mCRPC. The TROPIC trial showed cabazitaxel improved survival compared with mitoxantrone in patients who progressed on docetaxel. Both taxanes remain well-established treatments for patients fit enough to receive them.
Side effects: what to expect from each
Side effects matter when choosing between these options. Here's what each approach typically causes.
Lu-177 PSMA's most common side effects are fatigue, nausea, dry mouth, and low blood counts. Most are manageable and mild to moderate for many patients. Hair loss is not typical with radioligand therapy, which many patients find important. Treatment is given as one infusion every six weeks, with long breaks between doses. Bone pain may briefly flare after the first cycle, a sign treatment is reaching bone cancer. More details are in Lu-177 PSMA Pain Flare: What Every Patient Should Know.
Taxane chemotherapy causes different side effects. Docetaxel commonly causes hair loss, fatigue, fluid retention, and peripheral neuropathy (tingling or numbness in the hands and feet). Neutropenia (low white blood cell counts) is the most serious concern because it raises infection risk and needs careful monitoring. Cabazitaxel carries a similar risk of neutropenia. For patients already tired and in pain from advanced disease, chemotherapy can be physically hard, especially in the first few cycles.
Patients on hormone therapy with mCRPC treatment may develop bone thinning over time. Discuss bone health with your care team. If you explore supplements like those in the Ayurnomics Joint and Bone range, check for interactions with your cancer treatment first.
How to have this conversation with your oncologist
The decision between these treatments doesn't happen in a vacuum. Your oncologist will review your treatment history - which ARPIs you've taken and for how long, your current PSA levels, what your scans show, and how you're doing. Ask your oncologist these questions:
- Has a PSMA-PET scan been done? If not, should we get one before deciding on treatment?
- Can we delay chemotherapy, or is it urgent?
- Is Lu-177 PSMA available locally? If not, what are my options?
- If I try Lu-177 PSMA first and the disease progresses, can I still get chemotherapy later?
If your oncologist hasn't mentioned Lu-177 PSMA, ask about it directly. Access may be limited where you live. A second opinion on which treatment to try first is completely reasonable. More on how to navigate that process is covered in Lu-177 PSMA When Multiple Hormone Therapies Have Failed.
When to talk to your doctor
Talk to your oncologist right away if your PSA rises on hormone therapy, new lesions appear on scans, or your symptoms change or worsen. Ask if you need a PSMA-PET scan and whether radioligand therapy is an option for you. If you're thinking about traveling for Lu-177 PSMA treatment, get an eligibility review first. The Lutetium Therapy team can review your scans and lab results. If Lu-177 PSMA isn't right for you, you can get a second opinion on other treatment options through them.
This article is for general information only and is not medical advice. Always talk to your oncologist or care team about your specific situation.
Frequently asked questions
Can I have Lu-177 PSMA therapy instead of chemotherapy, or do I need chemo first?
As of March 2025, the FDA has approved Lu-177 PSMA therapy (Pluvicto) for mCRPC patients who have received an ARPI and where a doctor considers it appropriate to delay taxane chemotherapy. So chemotherapy is not required first in all cases. However, you must have a positive PSMA-PET scan result. If PSMA expression is too low on the scan, taxane chemotherapy may be the recommended next step instead.
What is the difference between docetaxel and cabazitaxel for prostate cancer?
Both are taxane chemotherapy drugs used in mCRPC. Docetaxel is typically the first taxane tried after hormone therapy stops working. Cabazitaxel is generally used if docetaxel has stopped working or was not tolerated. Both work by disrupting cancer cell division, but they have slightly different side-effect profiles and dosing schedules. Your oncologist will guide which is more appropriate based on your treatment history and overall health.
Does Lu-177 PSMA therapy cause hair loss?
Hair loss is not a typical side effect of Lu-177 PSMA radioligand therapy. Unlike taxane chemotherapy, which commonly causes alopecia (hair loss), Lu-177 PSMA delivers its radiation payload to PSMA-expressing cancer cells rather than broadly affecting fast-dividing cells like hair follicles. Fatigue, dry mouth, nausea, and low blood counts are more common concerns with Lu-177 PSMA.
What happens if my PSMA-PET scan is negative - can I still receive Lu-177 PSMA therapy?
If the PSMA-PET scan shows low or absent PSMA expression, Lu-177 PSMA therapy is not recommended, because the treatment relies on PSMA to find and bind to cancer cells. In this situation, taxane chemotherapy and other systemic options become the priority. A specialist in mCRPC can help you understand what a negative or borderline scan means for your specific case and what options remain.
Is Lu-177 PSMA therapy available outside the United States?
Lu-177 PSMA therapy is approved in the US (as Pluvicto) and in countries covered by the European Medicines Agency. Availability varies widely by country and by treatment centre. Patients in regions where access is limited - including parts of the GCC, Africa, and South Asia - sometimes travel to India, where the therapy is available at significantly lower cost. An eligibility review is the first step for international patients considering this route.
Can Lu-177 PSMA therapy and taxane chemotherapy both be used in the same treatment course?
In some cases, Lu-177 PSMA therapy and chemotherapy may be given at different points in the treatment course - one after the other - rather than at the same time. The sequencing depends on individual disease characteristics, eligibility, and your care team's judgment. There are ongoing clinical trials exploring combination approaches, but outside a clinical trial, they are not typically given simultaneously. Ask your oncologist whether sequencing or combination studies may be relevant to your situation.
